pEEG Monitoring Effect on Delirium, Ventilator Days, and PICS
Launched by FRASER HEALTH · Aug 24, 2023
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a special monitoring tool called processed electroencephalography (pEEG) can help manage sedation in patients who are on mechanical ventilation in the Intensive Care Unit (ICU). The researchers want to find out if using pEEG, along with a standard method for assessing sedation (the Richmond Agitation and Sedation Scale, or RASS), can reduce the number of days patients experience delirium, spend on a ventilator, and develop Post Intensive Care Syndrome (PICS), which can cause long-term effects after being in the ICU.
To participate in the study, patients must be at least 17 years old, admitted to the ICU, and on a ventilator for more than 48 hours while receiving sedation. They also need to be able to read and speak English and have access to a computer and the internet for follow-up assessments. Participants will be monitored while they receive care, and the study aims to help doctors improve how they manage sedation and support recovery for critically ill patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Admitted to ICU
- • 2. Receive mechanical ventilator support during ICU stay
- • 3. Require IV sedation or analgesic while ventilated
- • 4. Discharged home from the hospital
- • 5. Use of pEEG for sedation or analgesic titration
- • 6. Able to read and speak English
- • 7. Mechanically ventilated greater than 48 hours
- • 8. Aged 17 years +1 day or greater
- • 9. Consent to participate
- • 10. Participants need a computer with a keyboard, internet access, and email access for the questionnaires and assessment and be able to use computer and internet.
- Exclusion Criteria:
- • 1. Deceased during hospitalization
- • 2. Intubated at a hospital not included within the study \> 12 hours
- • 3. Discharge to rehabilitation facility, long term care, or other outpatient setting
- • 4. Inability to provide informed consent
- • 5. Currently enrolled in any other research study involving drugs or devices
- • 6. Is unable to be screened for delirium during ICU admission.
About Fraser Health
Fraser Health is a leading healthcare authority in British Columbia, Canada, dedicated to delivering high-quality, patient-centered care across diverse communities. As a prominent sponsor of clinical trials, Fraser Health is committed to advancing medical research and innovation to improve health outcomes. With a focus on ethical standards and rigorous scientific methodology, the organization collaborates with healthcare professionals, researchers, and patients to facilitate groundbreaking studies that address critical health challenges. Through its extensive network of hospitals and health services, Fraser Health aims to enhance the understanding of various medical conditions and contribute to the development of effective treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Abbotsford, British Columbia, Canada
Patients applied
Trial Officials
Fiona E Howarth
Principal Investigator
Fraser Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported